Bayer HealthCare’s U.S. subsidiary MEDRAD, Inc. has acquired Pathway Medical Technologies, Inc., headquartered at Kirkland in Washington state. The acquisition is intended to strengthen Bayer’s presence in the field of interventional cardiology. Pathway Medical Technologies is one of the leading manufacturers of products for mechanical removal of arterial deposits. The company’s products eliminate blockages in leg arteries, also known as peripheral arterial occlusive disease.
Jetstream™ devices from Pathway, for example, allow the physician to perform minimally invasive surgery to reinstate circulation in peripheral arteries where the build-up of deposits has led to vascular occlusion. Thanks to their special technology, Jetstream™ products are able to remove deposits from arteries without harming healthy tissue. The number of people with peripheral arterial occlusive disease in the U.S. alone is estimated at more than 12 million.
“The integration of Pathway Medical Technologies into the business of our Medrad subsidiary will support our strategy of offering new therapeutic options in the growing field of interventional medicine,” says Bayer HealthCare CEO Dr. Jörg Reinhardt. “Pathway’s products ideally supplement the current and future portfolio of Medrad Interventional.” Medrad Interventional’s product strategy envisions marketing Pathway’s Jetstream™ in combination with Bayer HealthCare’s AngioJet™ and Cotavance™ products as a comprehensive range of products to identify vascular diseases, restore blood circulation in the affected arteries and finally confirm the success of the treatment.